Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Average Rating of “Moderate Buy” from Brokerages

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $13.80.

OBIO has been the topic of a number of research reports. TD Cowen initiated coverage on Orchestra BioMed in a research note on Wednesday, December 10th. They issued a “buy” rating on the stock. Chardan Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a report on Thursday, November 13th. Barclays upped their price target on shares of Orchestra BioMed from $11.00 to $12.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Orchestra BioMed in a research report on Wednesday, October 8th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OBIO. Vanguard Group Inc. lifted its position in shares of Orchestra BioMed by 28.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after acquiring an additional 324,558 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Orchestra BioMed during the third quarter worth $3,386,000. Pathstone Holdings LLC purchased a new stake in shares of Orchestra BioMed during the third quarter valued at $2,495,000. Knott David M Jr boosted its position in shares of Orchestra BioMed by 95.0% in the 3rd quarter. Knott David M Jr now owns 195,000 shares of the company’s stock valued at $484,000 after purchasing an additional 95,000 shares during the period. Finally, AMH Equity Ltd purchased a new position in Orchestra BioMed in the 3rd quarter worth about $412,000. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Trading Up 5.3%

Shares of NASDAQ:OBIO opened at $4.16 on Wednesday. The company has a 50 day moving average of $4.47 and a 200-day moving average of $3.56. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32. The firm has a market cap of $234.89 million, a P/E ratio of -2.29 and a beta of 0.63. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.16.

Orchestra BioMed (NASDAQ:OBIO) last announced its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.74 million. Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%. As a group, analysts anticipate that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.